Aligos Therapeutics to Announce Third Quarter Results November 2, 2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS) has announced it will release its third quarter 2022 financial results on November 2, 2022, after U.S. market close. The company focuses on developing innovative therapeutics for viral infections and liver diseases, particularly targeting chronic hepatitis B and nonalcoholic steatohepatitis (NASH). Founded in 2018, Aligos aims to leverage its expertise to advance its drug pipeline effectively, positioning itself as a leader in these unmet medical needs.
- Focus on addressing unmet medical needs in viral and liver diseases.
- Potential to lead in chronic hepatitis B and NASH treatments.
- Strong emphasis on advancing drug pipeline with targeted antiviral therapies.
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company’s third quarter 2022 financial results on Wednesday, November 2, 2022 after the close of the U.S. financial markets.
About Aligos
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements.” Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 4, 2022 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Media Contact
Amy Jobe, Ph.D.
LifeSci Communications
+1 315 879 8192
ajobe@lifescicomms.com
Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
FAQ
What is the date of Aligos Therapeutics' Q3 2022 financial results announcement?
What therapeutic areas is Aligos Therapeutics focused on?
What is the stock symbol for Aligos Therapeutics?
